AZD5438 in Patients With Advanced Solid Malignancies

Phase I Study to Assess the Safety and Tolerability of AZD5438 in Patients With Advanced Solid Malignancies

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00088790

Enrollment

Unknown

Registered

2004-08-05

Start date

2004-07-31

Completion date

2005-12-31

Last updated

2011-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Keywords

advanced, solid, malignancies

Brief summary

Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.

Interventions

DRUGAZD5438

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Advanced solid malignancy * Cancer refractory to standard treatments or for which no standard therapy exits

Exclusion criteria

* Radiotherapy within 3 weeks of the start of treatment * Investigational product within the last 3 weeks * Systemic cytotoxic anti-cancer therapy within the last 3 weeks * Any significant clinical disorder that makes it undesirable for the patient to participate

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026